InterMune, Inc.(NASDAQ : ITMN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||2.71%||461.57||2.7%||$556.12m|
|GILD||Gilead Sciences, Inc.||2.20%||64.62||1.0%||$516.91m|
|VRTX||Vertex Pharmaceuticals, Inc.||2.02%||211.98||1.9%||$458.30m|
|ALXN||Alexion Pharmaceuticals, Inc.||1.11%||150.10||2.0%||$339.49m|
|CRSP||CRISPR Therapeutics AG||-0.73%||114.65||0.6%||$304.78m|
|BNGO||BioNano Genomics, Inc.||3.62%||7.15||0.0%||$275.81m|
|EXAS||EXACT Sciences Corp.||0.51%||121.64||18.4%||$251.13m|
|PACB||Pacific Biosciences of California, Inc.||1.70%||29.27||7.2%||$176.23m|
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, they are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as EsbrietÂ® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.